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In 2018, the Centers for Disease Control and Prevention announced drug overdose mortality hit a record high, with at least 70,237 Americans dying from an overdose \[[@CR1]\]. The impact of the overdose crisis is felt heavily in Florida: opioid-related deaths increased 35% between 2015 and 2016 statewide \[[@CR2]\]. Heroin-associated deaths in Miami-Dade County rose 826% between 2011 and 2016 \[[@CR2]\]. As Miami-Dade County consistently ranks first in HIV incidence nationwide, implementation of evidence-based HIV prevention coupled with overdose prevention was imperative \[[@CR3]\].

In 2016, Florida enacted the *Infectious Disease Elimination Act*, allowing a pilot syringe services program (SSP) but restricted to operate only in Miami, Florida: the University of Miami IDEA SSP. The World Health Organization, the Centers for Disease Control, and the United Nations have found SSPs to be cost-effective in reducing infectious disease burden \[[@CR4]--[@CR6]\]. In the year following the establishment of IDEA in Miami, approximately 518 PWID enrolled in services, and 795 kits of two 4 mg dose naloxone were distributed to participants. In addition to sterile needles and injection supplies, IDEA-SSP participants are provided with education on safer injection practices. This education includes instruction on the use of tester shots, using drugs with trusted friends, awareness of locations of previous overdoses, and unusually potent or otherwise toxic effects of commonly used drugs \[[@CR7]\].

Importantly, SSP services include community distribution of take-home naloxone kits \[[@CR8]\]. Take-home naloxone is an effective strategy for mitigating poor overdose outcomes as it reduces the time to administration versus activation of emergency medical services \[[@CR9]\]. Community naloxone distribution removes barriers to naloxone access, a critical feature for populations that experience significant hesitation when seeking medical care, partially due to uninsured status, systemic bias, and stigma associated with drug use. PWID are often first responders to overdoses and reverse an overwhelming majority of community overdoses. A national survey from 1996 to 2014 reported over 26,400 overdose reversals with PWID conducting 82.8% of reversals \[[@CR10]\]. Other research shows that PWID deploy take-home naloxone nearly ten times as frequently versus laypersons who do not use drugs---emphasizing the need to prioritize PWID in naloxone distribution efforts \[[@CR11]\].

Multiple systematic reviews have found take-home naloxone programs to be both safe and effective, leading to increased survival rates among participants as well as decreases in community overdose mortality rates \[[@CR12]--[@CR14]\]. Although systematic analyses have found take-home naloxone programs are effective in reducing overdose deaths among participants, few studies assess the impact of take-home naloxone programs on hospitalizations \[[@CR13]--[@CR15]\]. We present a study analyzing early effects of the IDEA-SSP on the incidence of opioid overdose-associated admissions at a county safety-net hospital in south Florida.
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We conducted a 25-month retrospective review of hospitalized patients' data at Jackson Memorial Hospital (JMH), a public hospital in Miami, Florida, that serves people without regard for insurance status. The period of review encompassed December 1, 2015, to January 1, 2018. JMH is the only safety-net hospital in Miami-Dade County and is within a half-mile proximity of the IDEA-SSP. Data were separated into two periods, with December 1, 2016---the establishment of the IDEA-SSP---as an index date. To increase the specificity of the query, data from December 1, 2016, to January 1, 2017, was excluded to allow time for sufficient community enrollment. An algorithm used by Tookes et al. was adapted using International Classification of Diseases, Tenth Revision (ICD-10) codes to query the JMH electronic discharge and billing records for patients aged 18--85 (see Supplemental Table [1](#MOESM1){ref-type="media"}) \[[@CR16]\]. A combination of ICD-10 codes for opioid use and injection-related infections (IRI) was used to identify people who inject opioids (PWIO). Opioid codes included ICD-10 diagnoses related to opioids (see Supplemental Table [2](#MOESM2){ref-type="media"}). IRI included endocarditis, bacteremia/sepsis, osteomyelitis, abscesses, and/or cellulitis diagnoses.

Medical records were abstracted for demographic information, length of stay (LOS), insurance status, and discharge status. Additionally, we independently analyzed publicly available Florida Department of Law Enforcement Medical Examiner Commission reports from 2012 to 2017 to identify regional and statewide trends in opioid-related mortality to compare to local findings (Fig. [1](#Fig1){ref-type="fig"}). Fig. 1Opioid-caused deaths in select Florida counties 2012--2017
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Descriptive statistics and frequency distributions for demographics, insurance status, and hospital use variables were utilized. Hospital use variables included discharge status and LOS for each hospitalization. Categorical data were described with numbers and percentages. Comparisons between pre- and post-index in frequencies of clinical and social demographic characteristics were analyzed by chi-square or Fisher's exact test. The chi-square test and Fisher's exact test can assess for independence between two variables when the comparing groups are independent and not correlated. Fisher's exact test was used for the analysis of demographic factors including race, age in year, and insurance status. Chi-square was used for the analysis of PWID overdose-associated admissions. Because some continuous variables, such as age and LOS, were not normally distributed, the Wilcoxon rank-sum test was used for the comparisons. The results were reported as median and interquartile range. All analyses were performed in SAS 9.4 (SAS Institute Inc., Cary, NC).

Results {#Sec4}
=======

Demographics {#Sec5}
------------

Three hundred two PWIO admissions were identified: 146 pre-index vs. 156 post-index (*p* = 0.12) (Table [1](#Tab1){ref-type="table"}). Race, sex, age, and insurance did not differ across pre- and post-index cohorts. Only 3% of PWIO had private insurance across the 2-year timespan. Approximately 60% of PWIO were uninsured, with no significant difference between cohorts (*p* = 0.88). Hospital mortality rates were not significantly different between the pre- and post-index cohorts. Nine (3%) patients died during the hospital stay as determined by an "expired" discharge status: five pre-index vs. four post-index (*p* = 0.74). Table 1PWIO demographicsPre-index, *n* = 146; \# (%)Post-index, *n* = 156; \# (%)*p* value**Biological sex0.46** Male103 (70.6)103 (66.0) Female43 (29.5)53 (34.0)**Race0.64** White118 (80.8)124 (79.5) Black27 (18.5)29 (18.6) Others1 (0.30)3 (1.9)**Ethnicity** Hispanic65 (44.5)57 (36.5)**0.16** Non-Hispanic81 (55.5)99 (63.5)**Age in years0.17** 16--2922 (15.1)30 (19.2) 30--3947 (32.2)47 (30.1) 40--4936 (24.7)48 (30.8) 50--5930 (20.6)20 (12.8) 60--659 (6.2)5 (3.2) 65--852 (1.4)6 (3.9)**Insurance status0.90** Uninsured85 (58.2)95 (60.9) Medicaid31 (21.2)34 (21.8) Medicare + Federal24 (16.4)21 (13.5) Private5 (3.4)4 (2.6) Others1 (0.7)2 (1.3)**Median length of stay**42**0.14Expired during study period**5 (3.4)4 (2.6)**0.74PWIO overdose-associated admissions**20 (13.7)6 (3.9)**0.0034**

Overdose sequela {#Sec6}
----------------

Overdose-associated admissions significantly changed in the post-index cohort vs. the pre-index cohort. In the pre-index cohort, 14% of admissions involved an overdose diagnosis, vs. 4% in the post-index cohort (*p* = 0.0034).

Florida opioid-caused deaths {#Sec7}
----------------------------

State medical examiner findings demonstrated overall increasing opioid-related deaths in Florida between 2010 and 2017. From 2014 to 2016, opioid-caused deaths increased. The rate of increase declined from 2016 to 2017 except in Pinellas and Miami-Dade counties, where opioid-related mortality decreased.

Discussion {#Sec8}
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Opioid-caused deaths increased in Florida following legislative efforts to close "pill mills" in 2012, with resulting increases seen in counterfeit opioid pills and heroin use \[[@CR15]\]. This data explores opioid epidemic-related morbidity and mortality in south Florida through the lens of hospital admissions following the implementation of IDEA-SSP. With the introduction of fentanyl and high-potency analogues into the drug supply, sharp increases in opioid mortality were seen statewide between 2014 and 2016 \[[@CR2], [@CR17]\]. Given the heretofore unmitigated statewide overdose crisis, it would be expected that hospital data would reflect regional trends of increasing overdose-associated admissions. However, following SSP implementation, while the number of PWIO in our cohort did not change significantly, overdoses reported in PWIO decreased significantly. The temporal association suggests that the IDEA-SSP community distribution of take-home naloxone may have produced early effects in mitigating overdose-associated morbidity and mortality.

Several statewide opioid epidemic interventions were implemented before and directly following the study period, including a concerted law enforcement effort to close "pill mills" \[[@CR17]\]. However, these statewide policies should theoretically affect all counties equally and thus do not temporally explain Miami-Dade's decline in overdose deaths as reported by the Florida Department of Law Enforcement Medical Examiners Commission (Fig. [1](#Fig1){ref-type="fig"}). During the study period, the IDEA-SSP distributed 795 naloxone kits to participants and 387 reversals were reported. Between 2016 and 2017, opioid-related mortality in Miami-Dade County declined 5%, from 321 deaths to 305 deaths. Similar declines were not seen in neighboring counties. Considered together, these data suggest early impacts of the first legal SSP in the state, operating in Miami-Dade County.

More low-barrier SSPs are needed across Florida to increase naloxone access among PWID and reduce statewide opioid-related morbidity and mortality. Due to negative experiences PWID have when receiving services in traditional health care settings, they may be less likely to visit such settings to access naloxone, highlighting the importance of establishing naloxone distribution programs in low-barrier settings where PWID may feel more comfortable---namely SSPs and other harm reduction modalities. Recent modeling simulating the impact of 13 naloxone distribution modalities on overdose deaths estimated expanding naloxone distribution through a single SSP can reduce a community's overdose deaths by 65% \[[@CR18]\].

Limitations to this study exist. The ICD-10 does not have diagnosis codes for injection drug use or sequelae. This study relied on a novel ICD-10 adaptation of an ICD-9-based algorithm using codes for drug use and infectious consequences \[[@CR16]\]. Additionally, the stigma associated with injection drug use remains widespread, and patients may not have reported use, resulting in under-documentation. Most importantly, our data do not imply causality between the establishment of the SSP and the decrease in opioid-associated admissions. Previous epidemiologic evaluations of SSPs describe lag times between community SSP implementation and decline in chronic infections \[[@CR19]\]. An analysis of HIV rates among PWID in Baltimore only noted a significant decline after 5 years of increasing SSP service coverage, with sustained decline demonstrated thereafter \[[@CR19]\]. Future research should explore longitudinal effects of the IDEA-SSP.

Despite these limitations, this study reveals a significant decrease in overdose-associated admissions among PWIO at a county safety-net hospital following the implementation of the IDEA-SSP in the setting of the contemporary Florida overdose crisis. Taken alongside medical examiner data, this study demonstrates trends of decreasing opioid overdose-related morbidity and mortality in Miami-Dade County. SSPs and take-home naloxone may impact the number of overdose-associated hospital admissions and warrant further study.
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=========================
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**Additional file 1: Supplementary Table 1.** JMH PWIO. This data consists of the 302 admission of people who inject opioids that we analyzed in this manuscript. **Additional file 2: Supplemental Table 2.** JMH PWIO ICD-10 Codes. This table contains the complete list of ICD-10 codes used for inclusion in the study as described in the Methods section.

IDEA-SSP

:   University of Miami IDEA Syringe Services Program

PWID

:   People who inject drugs

JMH

:   Jackson Memorial Hospital

ICD-10

:   International Classification of Diseases, Tenth Revision

IRI

:   Injection-related infections

PWIO

:   People who inject opioids

LOS

:   Length of stay
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